Rigel Pharmaceuticals Inc. (New) (RIGL)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 174
- Market Cap
- $871M
About Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
SentiSense also tracks daily options readings for Rigel Pharmaceuticals Inc. (New): IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Rigel Pharmaceuticals Inc. (New) stock analysis, sentiment tracking, and market intelligence on SentiSense.